{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:55:42Z","timestamp":1788789342097,"version":"build-2803163510"},"reference-count":42,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"abstract":"\n Importance<\/jats:title>\n Bipolar disorder, major depressive disorder, and schizophrenia are associated with substantial excess mortality, principally from cardiovascular disease. Identifying strategies to reduce this burden is a critical psychiatric priority.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate associations between initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors and all-cause mortality and major adverse cardiovascular events (MACEs) among adults with and without serious mental illness (SMI).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a retrospective target trial emulation within the TriNetX Analytics Network, a multinational federated electronic health record network. Adults initiating GLP-1 RAs or SGLT2 inhibitors were included using a new-user, active-comparator design with propensity score matching and separate psychiatric and nonpsychiatric cohorts. The study included all available data in the TriNetX network through the most recent database refresh. Data were queried and analyzed in March 2026, with prespecified follow-up intervals of 1, 4, and 10 years. Additional subgroup analyses were conducted following peer review in May 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n First-recorded GLP-1 RA vs SGLT2 inhibitor prescription.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was 4-year all-cause mortality; the key secondary outcome, 1-year mortality. Additional outcomes included 3- and 5-point MACEs and individual cardiovascular end points. Sensitivity analyses included diabetes stratification, exclusion of baseline heart failure and chronic kidney disease, and censoring at crossover. Exploratory analyses examined SMI subgroups, agent-specific effects, and combination therapy.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n For the primary 4-year analysis, 1\u202f528\u202f230 adults were propensity score matched (764\u202f115 pairs; 195\u202f184 pairs with serious mental illness [SMI] and 568\u202f931 pairs without SMI). The mean [SD] age in the GLP-1RA and SGLT2 inhibitor groups was 60.5 [12.0] and 60.2 [13.3] years, respectively, in the SMI cohort and 60.9 [12.2] and 60.6 [13.0] years, respectively, in the non-SMI cohort; 112\u202f911 [57.8%], 113\u202f488 [58.1%], 251\u202f679 [44.2%], and 260\u202f480 [45.8%] were female, respectively. Among participants with SMI, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (9585 of 195\u202f184 [4.91%] vs 12\u202f584 of 195\u202f184 [6.45%]; hazard ratio [HR], 0.76; 95% CI, 0.74-0.78; absolute risk difference [ARD], \u22121.54 percentage points; 95% CI, \u22121.68 to \u22121.39;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Among participants with SMI and type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower risks of 3-point MACE (HR, 0.77; 95% CI, 0.76-0.79), 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. In a separately matched 1-year SMI cohort, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (2898 of 198\u202f065; 1.46% vs 5624 of 198\u202f065; 2.84%; RR, 0.52; 95% CI, 0.49-0.54; ARD, \u22121.38 percentage points; 95% CI, \u22121.47 to \u22121.29;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). In 10-year exploratory analyses among participants with type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower mortality in the major depressive disorder (RR, 0.55; 95% CI, 0.53-0.56), bipolar disorder (RR, 0.57; 95% CI, 0.51-0.63), and schizophrenia (RR, 0.67; 95% CI, 0.59-0.75) groups (all\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The primary mortality association persisted across prespecified sensitivity analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI. Benefits were evident within 1 year, consistent across SMI subgroups, and driven by semaglutide and tirzepatide. Prospective randomized trials are warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2026.2574","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:39Z","timestamp":1787758239000},"source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness"],"prefix":"10.1001","author":[{"given":"Roger S.","family":"McIntyre","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang-James","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Norton College of Medicine at State University of New York, Upstate Medical University, Syracuse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T. H.","family":"Kwan","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada"},{"name":"Department of Internal Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"1","key":"yoi260041r1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10072-021-05348-2","article-title":"Bipolar disorder and the risk for stroke incidence and mortality: a meta-analysis.","volume":"43","author":"Yuan","year":"2022","journal-title":"Neurol Sci"},{"issue":"6","key":"yoi260041r2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/acps.12408","article-title":"A systematic review and meta-analysis of premature mortality in bipolar affective disorder.","volume":"131","author":"Hayes","year":"2015","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"yoi260041r3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jacc.2022.06.017","article-title":"Severe mental illness and cardiovascular disease: JACC state-of-the-art review.","volume":"80","author":"Goldfarb","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"yoi260041r4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness.","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"yoi260041r5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S2215-0366(25)00332-3","article-title":"Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis.","volume":"13","author":"Wagner","year":"2026","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"yoi260041r6","doi-asserted-by":"publisher","DOI":"10.1002\/pon.70314","article-title":"Breast cancer screening rates among patients with severe mental disorders (schizophrenia, bipolar disorder, and major depressive disorder). systematic literature review and meta-analysis.","volume":"34","author":"Aguilar-Romero","year":"2025","journal-title":"Psychooncology"},{"issue":"10","key":"yoi260041r7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamapsychiatry.2021.1818","article-title":"Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis.","volume":"78","author":"Ceban","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi260041r8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.25com16021","article-title":"Practitioners providing care for persons with severe mental disorders should routinely screen for metabolic dysfunction-associated steatotic liver disease.","volume":"86","author":"McIntyre","year":"2025","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"yoi260041r9","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1111\/dom.16568","article-title":"Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: a meta-analysis.","volume":"27","author":"Jamalinia","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"yoi260041r10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1017\/S1092852922001043","article-title":"The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia.","volume":"28","author":"Jawad","year":"2023","journal-title":"CNS Spectr"},{"issue":"10265","key":"yoi260041r11","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders.","volume":"396","author":"McIntyre","year":"2020","journal-title":"Lancet"},{"issue":"10328","key":"yoi260041r12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)02141-3","article-title":"Time for united action on depression: a Lancet-World Psychiatric Association Commission.","volume":"399","author":"Herrman","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"yoi260041r13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","article-title":"Discovery of GLP-1-based drugs for the treatment of obesity.","volume":"392","author":"Drucker","year":"2025","journal-title":"N Engl J Med"},{"key":"yoi260041r14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.amjcard.2025.09.039","article-title":"GLP-1 receptor agonists and cardiovascular outcomes in adults with diabetes and peripheral artery disease: an updated systematic review and meta-analysis.","volume":"258","author":"Shuja","year":"2026","journal-title":"Am J Cardiol"},{"issue":"4","key":"yoi260041r15","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1111\/dom.16228","article-title":"Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: a review and network meta-analysis.","volume":"27","author":"An","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"10531","key":"yoi260041r16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"issue":"20","key":"yoi260041r17","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients.","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"yoi260041r18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"yoi260041r19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial.","volume":"83","author":"Sass","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260041r20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug-related weight gain and its treatment.","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"11","key":"yoi260041r21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial.","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"yoi260041r22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator\u2014blinded, randomised controlled trial in Australia.","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"yoi260041r23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: a randomized clinical trial.","volume":"83","author":"Sass","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yoi260041r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14656566.2026.2621191","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality.","volume":"17","author":"McIntyre","year":"2026","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"yoi260041r25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2025.3828","article-title":"Tailored weight loss programs for adults with serious mental illness: a randomized clinical trial.","volume":"83","author":"Chinman","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"yoi260041r26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s11606-016-3712-4","article-title":"Diabetes and cardiovascular care among people with severe mental illness: a literature review.","volume":"31","author":"Mangurian","year":"2016","journal-title":"J Gen Intern Med"},{"key":"yoi260041r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2025.10476","article-title":"Pharmacological interventions to manage cardiometabolic outcomes in adults with severe mental illness: umbrella review.","author":"Carolan","year":"2025","journal-title":"Br J Psychiatry"},{"issue":"102867","key":"yoi260041r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102867","article-title":"Severe mental illness and infectious disease mortality: a systematic review and meta-analysis.","volume":"77","author":"Ronaldson","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10211","key":"yoi260041r30","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(19)32316-5","article-title":"A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study.","volume":"394","author":"Plana-Ripoll","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"yoi260041r31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"yoi260041r32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2215-0366(22)00237-1","article-title":"All-cause and cause-specific mortality among people with severe mental illness in Brazil\u2019s public health system, 2000-15: a retrospective study.","volume":"9","author":"Melo","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"103026","key":"yoi260041r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103026","article-title":"Diagnostic inequalities relating to physical healthcare among people with mental health conditions: a systematic review.","volume":"80","author":"Liberati","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"2","key":"yoi260041r34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors.","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"issue":"119487","key":"yoi260041r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119487","article-title":"The efficacy of lithium in the treatment of suicidal ideation, behavior and suicide: an updated systematic review and meta-analysis of randomized controlled trials.","volume":"387","author":"Wang","year":"2025","journal-title":"J Affect Disord"},{"issue":"8","key":"yoi260041r36","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials.","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"114622","key":"yoi260041r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review.","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"issue":"1","key":"yoi260041r38","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852925000124","article-title":"The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro-GDP): potential mechanistically informed therapeutics in the treatment and prevention of mental disorders.","volume":"30","author":"McIntyre","year":"2025","journal-title":"CNS Spectr"},{"issue":"7","key":"yoi260041r39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis.","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"yoi260041r40","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2025.6","article-title":"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.","volume":"37","author":"Zheng","year":"2025","journal-title":"Acta Neuropsychiatr"},{"issue":"4","key":"yoi260041r41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial.","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi260041r42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14740338.2024.2430306","article-title":"Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.","volume":"25","author":"McIntyre","year":"2026","journal-title":"Expert Opin Drug Saf"},{"key":"yoi260041r28","unstructured":"TriNetX. Accessed March 6, 2026. https:\/\/live.trinetx.com\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2852856\/jamapsychiatry_mcintyre_2026_oi_260041_1786118231.31592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:40Z","timestamp":1787758240000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2852856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.2574","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}